Neoadjuvant chemotheraphy in ovarian cancer

Expert Review of Anticancer Therapy

Volumn 4, Issue 4, 2004, Pages 639-647

  Park, Tjoung Won ^a   Kuhn, Walther C ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Improvement of tumor resectability; Induction therapy; Neoadjuvant chemotheraphy; Ovarian cancer; Prognosis; Quality of life

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HISTOPATHOLOGY; HUMAN; LAPAROTOMY; MINIMAL RESIDUAL DISEASE; OVARIECTOMY; OVARY CANCER; PATIENT SELECTION; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; STANDARD; TREATMENT OUTCOME; ADJUVANT THERAPY; CARCINOMA; DRUG ADMINISTRATION; OVARY TUMOR; PATHOLOGY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 85047689959     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.4.639     Document Type: Review

References (48)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80, 827-841 (1999).
2. Pfleiderer A. Malignome des Ovars. Urban und Schwarzenberg, München, Germany (1989).
3. Markman M. Report from the 24th Annual Meeting of the Society of Gynecologic Oncologists, February 7-10, 1993. J. Cancer Res. Clin. Oncol. 119, 759-760 (1993).
4. International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecological cancer. J. Epidemiol. Biostat. 3, 75 (1998).
5. Gruppo, Interegionale Co-operativo Oncologico Ginecologia. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo, Interegionale Co-operativo Oncologico Ginecologia. Lancet 2, 353-359 (1987).
6. Bertelsen K, Jakobsen A, Andersen JE et al. A randomized study of cyclophosphamide and cisplatinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol. Oncol. 28, 161-169 (1987).
7. Aure JC, Hoeg K Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet. Gynecol. 37, 1-9 (1971).
8. Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am. J. Obstet. Gynecol. 166, 504-511 (1992).
9. Griffiths CT, Fuller AF. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg. Clin. North Am. 58, 131-142 (1978).
10. Voest EE, van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk) as main objectives). Eur. J. Cancer Clin. Oncol. 25, 711-720 (1989).
11. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20, 1248-1259 (2002).
12. Kuhn W, Florack G, Roder J et al. The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian carcinoma FIGO III and FIGO IV. Int. J. Gynecol. Cancer 8, 56-63 (1998).
13. Naik P, Nordin A, Cross PA et al. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol. Oncol. 78, 171-175 (2000).
14. Nicklin JL, Copeland LJ, O'Toole RV et al. Splenectomy as part of cytoreductive surgery for ovarian carcinoma. Gynecol. Oncol. 58, 244-247 (1995).
15. Heintz AP, Hacker NF, Berek JS et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet. Gynecol. 67, 783-788 (1986).
16. Potter ME, Partridge EE, Hatch KD et al. Primary surgical therapy of ovarian cancer: how much and when. Gynecol. Oncol. 40, 195-200 (1991).
17. Neijt JP, ten Bokkel Huinink WW, van der Burg ME et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. J. Clin. Oncol. 5, 1157-1168 (1987).
18. Hacker NF, Berek JS, Lagasse LD et al. Primary cytoreductive surgery for epithelial ovarian cancer Obstet. Gynecol. 61, 413-420 (1983).
19. Heintz AP, Van Oosterom AT, Trimbos JB et al. The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. Gynecol. Oncol. 30, 347-358 (1988).
20. Hoskins WJ, Bundy BN, Thigpen JT et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 47, 159-166 (1992).
21. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170, 974-979 (1994).
22. Vergote I, De Wever I, Tjalma W et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol. 71, 431-436 (1998).
23. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69, 103-108 (1998).
24. Burghardt E, Girardi F, Lahousen M et al. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol. Oncol. 40, 103-106 (1991).
25. Friedlander ML, Hedley DW, Swanson C et al. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J. Clin. Oncol. 6, 282-290 (1988).
26. Kuhn W, Pache L, Schmalfeldt B et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol. 55, 401-409 (1994).
27. Chan KK. Does the surgeon matter in the management of ovarian cancer? Br. J. Cancer 80, 1492-1493 (1999).
28. Cannistra SA. Cancer of the ovary. N. Engl. J. Med. 329, 1550-1559 (1993).
29. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859-866 (2003).
30. Weese JL, Harbison SP, Stiller GD et al. Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma. Surgery 128, 564-571 (2000).
31. Wilke H, Fink U. Multimodal therapy for adenocarcinoma of the esophagus and esophagogastric junction. N. Engl. J. Med. 335, 509-510 (1996).
32. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Co-operative Group of the European Organization for Research and Treatment of Cancer. N. Engl. J. Med. 332, 629-634 (1995).
33. Rose PG, Nerenstone S, Brady M. A Phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proc. Am. Soc. Clin. Oncol. 21 (2002).
34. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst. 92, 699-708 (2000).
35. Vermorken JB, Pecorelli S. Clinical trials in patients with epithelial ovarian cancer: past, present and future. Eur. J. Surg. Oncol. 22, 455-466 (1996).
36. Lawton FG, Redman CW, Luesley DM et al. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet. Gynecol. 73, 61-65 (1989).
37. Jacob JH, Gershenson DM, Morris M et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol. Oncol. 42, 146-150 (1991).
38. Lim JT, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin. Oncol. (R. Coll. Radiol.) 5, 198-202 (1993).
39. Onnis A, Marchetti M, Padovan P et al. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur. J. Gynecol. Oncol. 17, 393-396 (1996).
40. Schwartz PE, Rutherford TJ, Chambers JT et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol. Oncol. 72, 93-99 (1999).
41. Kuhn W, Rutke S, Spathe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92, 2585-2591 (2001).
42. Kayikcioglu F, Kose MF, Boran N et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 11, 466-470 (2001).
43. Ansquer Y, Leblanc E, Clough K et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 91, 2329-2334 (2001).
44. Mazzeo F, Berliere M, Kerger J et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol. Oncol. 90, 163-169 (2003).
45. Ushijima K, Ota S, Komai K et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int. Surg. 87, 185-190 (2002).
46. Chan YM, Ng TY, Ngan HY et al. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol. Oncol. 88, 9-16 (2003).
47. Shridhar V, Bible KC, Staub J et al. Loss of expression of a new member of the DNA protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 61, 4258-4265 (2001).
48. Mansouri A, Ridgway LD, Korapati AL et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J. Biol. Chem. 278, 19245-19256 (2003).